Catalyst Biosciences Stock Price, News & Analysis (NASDAQ:CBIO)

$10.49 0.56 (5.64 %)
(As of 12/18/2017 07:58 AM ET)
Previous Close$9.93
Today's Range$9.80 - $10.65
52-Week Range$3.11 - $18.88
Volume376,700 shs
Average Volume461,073 shs
Market Capitalization$45.22 million
P/E RatioN/A
Dividend YieldN/A
Beta1.89

About Catalyst Biosciences (NASDAQ:CBIO)

Catalyst Biosciences logoCatalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company's advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.

Receive CBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CBIO
CUSIP87611R30
Phone650-266-8674

Debt

Debt-to-Equity RatioN/A
Current Ratio3.58%
Quick Ratio3.58%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$400,000.00
Price / Sales113.03
Cash FlowN/A
Price / CashN/A
Book Value$20.03 per share
Price / Book0.52

Profitability

Trailing EPS($13.12)
Net Income$-16,940,000.00
Net Margins-2,438.50%
Return on Equity-91.67%
Return on Assets-55.28%

Miscellaneous

Employees10
Outstanding Shares4,310,000

Catalyst Biosciences (NASDAQ:CBIO) Frequently Asked Questions

What is Catalyst Biosciences' stock symbol?

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work?

Catalyst Biosciences shares reverse split on the morning of Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences Inc (NASDAQ:CBIO) issued its quarterly earnings results on Thursday, May, 11th. The biopharmaceutical company reported ($4.57) EPS for the quarter, beating the Zacks' consensus estimate of ($5.14) by $0.57. The biopharmaceutical company earned $0.27 million during the quarter. Catalyst Biosciences had a negative return on equity of 91.67% and a negative net margin of 2,438.50%. View Catalyst Biosciences' Earnings History.

When will Catalyst Biosciences make its next earnings announcement?

Catalyst Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, March, 6th 2018. View Earnings Estimates for Catalyst Biosciences.

Where is Catalyst Biosciences' stock going? Where will Catalyst Biosciences' stock price be in 2017?

3 brokerages have issued 12-month price objectives for Catalyst Biosciences' shares. Their predictions range from $10.00 to $19.00. On average, they anticipate Catalyst Biosciences' stock price to reach $13.33 in the next twelve months. View Analyst Ratings for Catalyst Biosciences.

Who are some of Catalyst Biosciences' key competitors?

Who are Catalyst Biosciences' key executives?

Catalyst Biosciences' management team includes the folowing people:

  • Nassim Usman Ph.D., President, Chief Executive Officer, Director (Age 51)
  • Fletcher Payne, Chief Financial Officer
  • Andrew Hetherington, Vice President - Manufacturing Operations
  • Arwa Shurrab, Vice President - Regulatory Affairs
  • Jeffrey Landau, Vice President - Business Development
  • Howard Levy Ph.D., Chief Medical Officer
  • Jamie Siegel M.D., Head - Clinical Development
  • Errol B. De Souza Ph.D., Director (Age 63)
  • Stephen Anthony Hill M.D., Director (Age 59)
  • Jeffrey Himawan Ph.D., Director (Age 52)

Who owns Catalyst Biosciences stock?

Catalyst Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (4.03%). View Institutional Ownership Trends for Catalyst Biosciences.

Who bought Catalyst Biosciences stock? Who is buying Catalyst Biosciences stock?

Catalyst Biosciences' stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP. View Insider Buying and Selling for Catalyst Biosciences.

How do I buy Catalyst Biosciences stock?

Shares of Catalyst Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catalyst Biosciences' stock price today?

One share of Catalyst Biosciences stock can currently be purchased for approximately $10.49.

How big of a company is Catalyst Biosciences?

Catalyst Biosciences has a market capitalization of $45.22 million and generates $400,000.00 in revenue each year. The biopharmaceutical company earns $-16,940,000.00 in net income (profit) each year or ($13.12) on an earnings per share basis. Catalyst Biosciences employs 10 workers across the globe.

How can I contact Catalyst Biosciences?

Catalyst Biosciences' mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-8674 or via email at [email protected]


MarketBeat Community Rating for Catalyst Biosciences (CBIO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  84 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  190
MarketBeat's community ratings are surveys of what our community members think about Catalyst Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Catalyst Biosciences (NASDAQ:CBIO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.00$31.50$31.50$31.50
Price Target Upside: 305.59% upside634.27% upside634.27% upside634.27% upside

Catalyst Biosciences (NASDAQ:CBIO) Consensus Price Target History

Price Target History for Catalyst Biosciences (NASDAQ:CBIO)

Catalyst Biosciences (NASDAQ:CBIO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2017B. RileyInitiated CoverageBuy$19.00HighView Rating Details
6/12/2017Chardan CapitalInitiated CoverageBuy -> Buy$10.00HighView Rating Details
6/6/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$11.00LowView Rating Details
10/6/2016HC WainwrightReiterated RatingBuy$52.50N/AView Rating Details
6/30/2016Rodman & RenshawInitiated CoverageBuy$52.50N/AView Rating Details
(Data available from 12/18/2015 forward)

Earnings

Catalyst Biosciences (NASDAQ:CBIO) Earnings History and Estimates Chart

Earnings by Quarter for Catalyst Biosciences (NASDAQ:CBIO)

Catalyst Biosciences (NASDAQ CBIO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018($1.59)N/AView Earnings Details
8/3/20176/30/2017($1.46)($2.53)$0.11 millionViewN/AView Earnings Details
5/11/20173/31/2017($5.14)($4.57)$0.27 millionViewN/AView Earnings Details
3/8/201712/31/2016($5.63)($4.68)$0.10 million$0.10 millionViewN/AView Earnings Details
11/3/2016Q3($0.46)($0.40)$0.10 million$0.11 millionViewN/AView Earnings Details
8/4/2016Q216($0.31)($0.42)$0.10 million$0.11 millionViewN/AView Earnings Details
11/5/2014Q314($0.22)($0.14)$0.03 millionViewListenView Earnings Details
8/6/2014Q214($0.33)($0.24)$0.04 millionViewListenView Earnings Details
5/7/2014Q114($0.37)($0.44)$3.54 million$0.09 millionViewListenView Earnings Details
2/13/2014Q413($0.39)($0.40)$0.59 million$0.09 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.37)($0.37)$0.35 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.34)($0.24)$600.00 million$3.54 millionViewListenView Earnings Details
2/13/2013Q4 2012($0.31)($0.47)$0.83 million$0.59 millionViewListenView Earnings Details
11/6/2012Q312($0.39)($0.24)$0.87 million$0.77 millionViewN/AView Earnings Details
8/7/2012$0.39$0.43ViewN/AView Earnings Details
5/3/2012($0.25)$0.07ViewN/AView Earnings Details
2/21/2012($0.30)($0.29)ViewN/AView Earnings Details
11/1/2011($0.20)($0.27)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Catalyst Biosciences (NASDAQ:CBIO) Earnings Estimates

Current Year EPS Consensus Estimate: $-6.85 EPS
Next Year EPS Consensus Estimate: $-5.4 EPS

Dividends

Catalyst Biosciences (NASDAQ:CBIO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/4/2015$0.578/12/20158/14/20158/19/2015
(Data available from 1/1/2013 forward)

Insider Trades

Catalyst Biosciences (NASDAQ CBIO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 31.47%
Insider Trades by Quarter for Catalyst Biosciences (NASDAQ:CBIO)
Institutional Ownership by Quarter for Catalyst Biosciences (NASDAQ:CBIO)

Catalyst Biosciences (NASDAQ CBIO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/17/2015Fletcher PayneCFOBuy10,000$2.00$20,000.00View SEC Filing  
12/17/2015Nassim UsmanCEOBuy4,000$2.00$8,000.00View SEC Filing  
12/17/2015Stephen A HillDirectorBuy5,000$2.03$10,150.00View SEC Filing  
12/5/2013Scott Sandellmajor shareholderSell1,000$5.13$5,130.00View SEC Filing  
11/21/2013M James Barrettmajor shareholderSell5,333$5.16$27,518.28View SEC Filing  
5/10/2013Julia R BrownDirectorBuy6,000$5.09$30,540.00View SEC Filing  
3/11/2013Stephen A HillCEOBuy20,000$4.43$88,600.00View SEC Filing  
11/16/2012Bvf Partners L P/IlMajor ShareholderBuy595,000$4.00$2,380,000.00View SEC Filing  
11/8/2012Bvf Partners L P/IlMajor ShareholderBuy72,429$4.03$291,888.87View SEC Filing  
11/2/2012Bvf Partners L P/IlMajor ShareholderBuy139,700$4.05$565,785.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Catalyst Biosciences (NASDAQ CBIO) News Headlines

Source:
DateHeadline
Catalyst Biosciences (CBIO) Names Edward Williams to Board - StreetInsider.comCatalyst Biosciences (CBIO) Names Edward Williams to Board - StreetInsider.com
www.streetinsider.com - December 15 at 6:13 PM
Today’s Research Reports on Trending Tickers: Catalyst Biosciences and Valeant PharmaceuticalsToday’s Research Reports on Trending Tickers: Catalyst Biosciences and Valeant Pharmaceuticals
finance.yahoo.com - December 15 at 9:30 AM
Catalyst Biosciences Announces Appointment of Edward Williams to its Board of DirectorsCatalyst Biosciences Announces Appointment of Edward Williams to its Board of Directors
finance.yahoo.com - December 14 at 9:16 AM
Catalyst Biosciences (CBIO) Highlights Interim Phase 1/2 CB 2679d/ISU304 Results - StreetInsider.comCatalyst Biosciences (CBIO) Highlights Interim Phase 1/2 CB 2679d/ISU304 Results - StreetInsider.com
www.streetinsider.com - December 11 at 5:50 PM
Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology ... - GlobeNewswire (press release)Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology ... - GlobeNewswire (press release)
globenewswire.com - December 10 at 9:12 AM
Catalyst Biosciences (CBIO) Coverage Initiated at B. RileyCatalyst Biosciences (CBIO) Coverage Initiated at B. Riley
www.americanbankingnews.com - December 8 at 11:50 PM
Comparing Biogen (BIIB) & Catalyst Biosciences (CBIO)Comparing Biogen (BIIB) & Catalyst Biosciences (CBIO)
www.americanbankingnews.com - December 1 at 3:34 PM
Comparing Catalyst Biosciences (CBIO) & Anika Therapeutics (ANIK)Comparing Catalyst Biosciences (CBIO) & Anika Therapeutics (ANIK)
www.americanbankingnews.com - November 29 at 11:30 PM
Was Catalyst Biosciences Inc’s (CBIO) EPS Decline A Part Of Broader Industry Downturn?Was Catalyst Biosciences Inc’s (CBIO) EPS Decline A Part Of Broader Industry Downturn?
finance.yahoo.com - November 29 at 5:55 PM
Catalyst Biosciences Strengthens Clinical Hemophilia Programs with Additions to its Senior Leadership Team - GlobeNewswire (press release)Catalyst Biosciences Strengthens Clinical Hemophilia Programs with Additions to its Senior Leadership Team - GlobeNewswire (press release)
globenewswire.com - November 29 at 9:12 AM
Catalyst Biosciences Strengthens Clinical Hemophilia Programs with Additions to its Senior Leadership TeamCatalyst Biosciences Strengthens Clinical Hemophilia Programs with Additions to its Senior Leadership Team
finance.yahoo.com - November 28 at 5:34 PM
Today’s Research Reports on Trending Tickers: Catalyst Biosciences and Corcept TherapeuticsToday’s Research Reports on Trending Tickers: Catalyst Biosciences and Corcept Therapeutics
finance.yahoo.com - November 20 at 6:07 PM
 Catalyst Biosciences, Inc. (CBIO) Receives Average Rating of "Strong Buy" from Brokerages Catalyst Biosciences, Inc. (CBIO) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - November 15 at 3:24 AM
Catalyst Biosciences Inc (CBIO): Time For A Financial Health CheckCatalyst Biosciences Inc (CBIO): Time For A Financial Health Check
finance.yahoo.com - November 14 at 5:29 PM
Catalyst Biosciences, Inc. :CBIO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017Catalyst Biosciences, Inc. :CBIO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
finance.yahoo.com - November 13 at 11:30 PM
Catalyst Biosciences, Inc. (CBIO) Upgraded by Zacks Investment Research to BuyCatalyst Biosciences, Inc. (CBIO) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - November 8 at 8:28 PM
Kadmon Holdings (KDMN) & Catalyst Biosciences (CBIO) Critical AnalysisKadmon Holdings (KDMN) & Catalyst Biosciences (CBIO) Critical Analysis
www.americanbankingnews.com - November 7 at 10:58 AM
Catalyst Biosciences (CBIO) Announces Oral Presentation on Interim Phase 1/2 Data of Subcutaneous CB 2679d ... - StreetInsider.comCatalyst Biosciences (CBIO) Announces Oral Presentation on Interim Phase 1/2 Data of Subcutaneous CB 2679d ... - StreetInsider.com
www.streetinsider.com - November 2 at 5:44 PM
Catalyst Biosciences Reports Third Quarter 2017 Operating ... - GlobeNewswire (press release)Catalyst Biosciences Reports Third Quarter 2017 Operating ... - GlobeNewswire (press release)
globenewswire.com - November 2 at 5:44 PM
Catalyst Biosciences Reports Third Quarter 2017 Operating & Financial Results and Provides Corporate UpdateCatalyst Biosciences Reports Third Quarter 2017 Operating & Financial Results and Provides Corporate Update
finance.yahoo.com - November 2 at 5:43 PM
Catalyst Biosciences (CBIO) Announces Oral Presentation on Interim Phase 1/2 Data of Subcutaneous CB 2679d/ISU304 in Hemophilia B Patients at ASHCatalyst Biosciences (CBIO) Announces Oral Presentation on Interim Phase 1/2 Data of Subcutaneous CB 2679d/ISU304 in Hemophilia B Patients at ASH
www.streetinsider.com - November 2 at 3:51 AM
Catalyst Biosciences Announces Oral Presentation on Interim Phase 1/2 Data of Subcutaneous CB 2679d/ISU304 in Hemophilia B Patients at American Society for HematologyCatalyst Biosciences Announces Oral Presentation on Interim Phase 1/2 Data of Subcutaneous CB 2679d/ISU304 in Hemophilia B Patients at American Society for Hematology
finance.yahoo.com - November 1 at 5:46 PM
Catalyst Biosciences Announces Oral Presentation on Interim Phase 1/2 Data of Subcutaneous CB 2679d/ISU304 in Hemophilia B Patients at American Society for HematologyCatalyst Biosciences Announces Oral Presentation on Interim Phase 1/2 Data of Subcutaneous CB 2679d/ISU304 in Hemophilia B Patients at American Society for Hematology
finance.yahoo.com - November 1 at 5:46 PM
LifeSci Advisors Announces 11th Board Appointment Through Board Placement InitiativeLifeSci Advisors Announces 11th Board Appointment Through Board Placement Initiative
finance.yahoo.com - October 31 at 6:10 PM
Catalyst Biosciences (CBIO) Appoints Andrea Hunt to BoardCatalyst Biosciences (CBIO) Appoints Andrea Hunt to Board
www.streetinsider.com - October 26 at 10:12 PM
Catalyst Biosciences (CBIO) Appoints Andrea Hunt to Board - StreetInsider.comCatalyst Biosciences (CBIO) Appoints Andrea Hunt to Board - StreetInsider.com
www.streetinsider.com - October 26 at 5:11 PM
Catalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of Directors - GlobeNewswire (press release)Catalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of Directors - GlobeNewswire (press release)
globenewswire.com - October 26 at 8:40 AM
Catalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of DirectorsCatalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of Directors
finance.yahoo.com - October 26 at 8:40 AM
30 Stocks Moving In Tuesdays Pre-Market Session - Benzinga30 Stocks Moving In Tuesday's Pre-Market Session - Benzinga
www.benzinga.com - October 25 at 12:17 AM
Catalyst Biosciences (CBIO), Mosaic Biosciences Enter Pact to Develop Intravitreal Anti-Complement Factor 3 (C3 ... - StreetInsider.comCatalyst Biosciences (CBIO), Mosaic Biosciences Enter Pact to Develop Intravitreal Anti-Complement Factor 3 (C3 ... - StreetInsider.com
www.streetinsider.com - October 25 at 12:17 AM
Catalyst Biosciences and Mosaic Biosciences Enter into Strategic Collaboration to Develop Intravitreal Anti-Complement Factor 3 (C3) Products for the Treatment of Dry AMD and Other Retinal DiseasesCatalyst Biosciences and Mosaic Biosciences Enter into Strategic Collaboration to Develop Intravitreal Anti-Complement Factor 3 (C3) Products for the Treatment of Dry AMD and Other Retinal Diseases
finance.yahoo.com - October 24 at 7:15 PM
Reviewing VIVUS (VVUS) & Catalyst Biosciences (CBIO)Reviewing VIVUS (VVUS) & Catalyst Biosciences (CBIO)
www.americanbankingnews.com - October 4 at 6:04 PM
Head to Head Review: Sonoma Pharmaceuticals (SNOA) and Catalyst Biosciences (CBIO)Head to Head Review: Sonoma Pharmaceuticals (SNOA) and Catalyst Biosciences (CBIO)
www.americanbankingnews.com - October 4 at 6:04 PM
Critical Survey: Vericel Corp (VCEL) versus Catalyst Biosciences (CBIO)Critical Survey: Vericel Corp (VCEL) versus Catalyst Biosciences (CBIO)
www.americanbankingnews.com - September 27 at 4:28 AM
Catalyst Biosciences (CBIO) Says it Was Granted FDA Orphan Drug Designation for Subcutaneous Recombinant ... - StreetInsider.comCatalyst Biosciences (CBIO) Says it Was Granted FDA Orphan Drug Designation for Subcutaneous Recombinant ... - StreetInsider.com
www.streetinsider.com - September 26 at 4:00 PM
Catalyst Biosciences Granted FDA Orphan Drug Designation for Subcutaneous Recombinant Human Factor IX Variant for Treatment of Hemophilia BCatalyst Biosciences Granted FDA Orphan Drug Designation for Subcutaneous Recombinant Human Factor IX Variant for Treatment of Hemophilia B
finance.yahoo.com - September 26 at 8:34 AM
Catalyst Biosciences Announces Successful Completion of First Subcutaneous Dosing Cohort in Ongoing Hemophilia B Clinical TrialCatalyst Biosciences Announces Successful Completion of First Subcutaneous Dosing Cohort in Ongoing Hemophilia B Clinical Trial
finance.yahoo.com - September 25 at 7:47 PM
Comparing Opiant Pharmaceuticals (OPNT) and Catalyst Biosciences (CBIO)Comparing Opiant Pharmaceuticals (OPNT) and Catalyst Biosciences (CBIO)
www.americanbankingnews.com - September 25 at 12:18 PM
Catalyst Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference - GlobeNewswire (press release)Catalyst Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 22 at 10:19 AM
Catalyst Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare ConferenceCatalyst Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 22 at 10:19 AM
Catalyst Biosciences (CBIO) and Kamada (KMDA) Financial SurveyCatalyst Biosciences (CBIO) and Kamada (KMDA) Financial Survey
www.americanbankingnews.com - September 13 at 2:28 AM
Catalyst Biosciences (CBIO) Says it Was Issued Asia Patents ... - StreetInsider.comCatalyst Biosciences (CBIO) Says it Was Issued Asia Patents ... - StreetInsider.com
www.streetinsider.com - September 11 at 10:36 PM
Catalyst Biosciences Announces Issuance of Asia Patents Covering Factor IX Hemophilia ProgramCatalyst Biosciences Announces Issuance of Asia Patents Covering Factor IX Hemophilia Program
finance.yahoo.com - September 11 at 5:35 PM
Catalyst Biosciences (CBIO) & its Peers Financial ReviewCatalyst Biosciences (CBIO) & its Peers Financial Review
www.americanbankingnews.com - September 9 at 2:08 PM
Catalyst Biosciences (CBIO) Reports Positive Factor IX Clinical DataCatalyst Biosciences (CBIO) Reports Positive Factor IX Clinical Data
www.streetinsider.com - September 8 at 5:22 PM
Catalyst Biosciences Announces Positive Factor IX Clinical Data - GlobeNewswire (press release)Catalyst Biosciences Announces Positive Factor IX Clinical Data - GlobeNewswire (press release)
globenewswire.com - September 8 at 3:10 AM
Catalyst Biosciences Announces Positive Factor IX Clinical DataCatalyst Biosciences Announces Positive Factor IX Clinical Data
finance.yahoo.com - September 6 at 5:01 PM
ETFs with exposure to Catalyst Biosciences, Inc. : September 6, 2017ETFs with exposure to Catalyst Biosciences, Inc. : September 6, 2017
finance.yahoo.com - September 5 at 11:30 PM
Catalyst Biosciences, Inc. :CBIO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017Catalyst Biosciences, Inc. :CBIO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 5:03 PM
Reviewing Catalyst Biosciences (CBIO) and Myovant Sciences (MYOV)Reviewing Catalyst Biosciences (CBIO) and Myovant Sciences (MYOV)
www.americanbankingnews.com - August 24 at 4:24 PM

SEC Filings

Catalyst Biosciences (NASDAQ:CBIO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Catalyst Biosciences (NASDAQ:CBIO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Catalyst Biosciences (NASDAQ CBIO) Stock Chart for Monday, December, 18, 2017

Loading chart…

This page was last updated on 12/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.